Axsome Therapeutics, Inc.

Good morning, and welcome to the Axiom Therapeutics conference call. Currently, all participants are in listen-only mode. Later, there will be a question and answer session, and instructions will follow at that time. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, today's conference call is being recorded. I would now like to turn the conference over to your host, Mark Jacobson, Chief Operating Officer at Axiom Therapeutics. Please go ahead.

Thank you, Operator. Good morning and thank you all for joining us on today's conference call. This morning we issued our earnings press release providing a corporate update and details of the company's financial results for the third quarter of 2022. The release crossed the wire a short time ago and is available on our website at axon.com. During today's call, we will be making certain forward-looking statements. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our investigational agents, our clinical and non-clinical plans, our plans to present or report additional data, the anticipated conduct and the source of future clinical trials, regulatory plans, future research and development plans, our commercial plans regarding synosy, ovality, and our pipeline products, revenue projections, and possible intended use of cash and investments. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with Securities and Exchange Commission, including our quarterly and annual reports. Your caution not to place undue reliance on these forward-looking statements, which are only made as of today's date, and the company disclaims any obligation to update such statements. Joining me on the call today are Dr. Ariel Tabuto, Chief Executive Officer, Nick Peasy, Chief Financial Officer, and Lori Engelbert, Executive Vice President of Commercial and Business Development. Ariel will first provide an overview of the company and then review recent developments and upcoming milestones. Following Ariel, Nick will review our financial results, and Lori will provide a commercial update. We will then open the line for questions. Questions will be taken in the order they are received. And with that, I will turn the call over to Ariel.

Thank you, Mark. Good morning, everyone, and thank you all for joining Axon Therapeutics' third quarter 2022 financial results and business update conference call. The past few months have been pivotal and exciting at Axon. Our transformation into a commercial stage, fully integrated, research and development-driven, CNS-focused biopharmaceutical company has accelerated. with the commercialization of Synose for EDS associated with narcolepsy and obstructive sleep apnea, and now with the launch of Abelity for the treatment of MDD in adults. In addition, our broad and differentiated CNS pipeline continues to progress. The third quarter was the first full quarter of sales for Synose, and the results demonstrate the efficiency of our commercial approach. Current and future initiatives and potential indication expansion for Synose bode well for the continued growth of this differentiated product with significant market potential. Nick will provide more details on our financial performance. We are thrilled to have recently launched Orvelity, making this important new treatment available to the millions of adult patients living with MDD in the US. Orvelity is now helping to address a major public health concern given the current mental health epidemic. While still very early days, with only 12 days on the market, Laurie will provide some comments on our initial experience. Complementing our commercial progress, our broad late-stage CNS pipeline continues to progress, setting the stage for potentially continued significant value creation over the near, intermediate, and long term. This pipeline includes AXS07 for migraine, AXS07, AXS05 for Alzheimer's disease agitation, AXS-12 for narcolepsy, AXS-14 for fibromyalgia, as well as ADHD, a potential new indication for sorianfetol or senosine. With regards to AXS-07 for the acute treatment of migraine, we completed a type A meeting with the FDA in the third quarter. Based on the meeting results, we intend to resubmit the AXS-07 NDA in the third quarter of 2023. As a reminder, no additional clinical efficacy or safety trials have been requested by the FDA for resubmission of the NDA. With regards to our Alzheimer's disease agitation program, we recently initiated the ADVANCE-II study, which is a Phase III randomized, double-blind, placebo-controlled, multi-centered trial to assess the efficacy and safety of AXS05 for the treatment of Alzheimer's disease agitation. Concurrent with the initiation of the ADVANCE-II trial, we have concluded the ACCORD randomized withdrawal trial as planned. Top-line results from the ACCORD trial are now on track for the fourth quarter of 2022. For AXS-12, our product candidate for the treatment of narcolepsy, enrollment in the Symphony Phase III trial is progressing, and top-line results continue to be anticipated in the first half of 2023. For AXS-14, our product candidate for the treatment of fibromyalgia Manufacturing and other activities related to the planned submission of an NDA are ongoing, and we expect to submit the NDA for this product in 2023. With regards to psori-amphetol, or Synose, for the treatment of ADHD, we are preparing to initiate a Phase 2-3 multicenter randomized double-blind placebo-controlled trial in the syndication in the fourth quarter of this year. The Axon team is therefore busy and excited as we prepare to deliver on continued ongoing commercial progress and near and intermediate term pipeline milestones, which include clinical trial readouts, clinical trial initiations, and NDA filings over the remainder of this year and through 2023. I will now turn the call over to Nick, who will provide a financial update.

Thank you, Ariel, and good morning, everyone. Today, we'll discuss our third quarter results and provide some financial guidance. Total revenue in the third quarter of 2022 consisted of net sales of Synosi, Synosi generated U.S. net sales of $16.8 million in the third quarter, which was the first full quarter of sales. As a reminder, the acquisition of Synosi in the U.S. was completed on May 9th, so there were no Axum-generated sales in the prior year comparable period. We remain on track to close the ex-U.S. portion in the fourth quarter of 2022. Cost of product sales for the quarter were $1.9 million. R&D expenses were $14.9 million for the third quarter and $13.2 million for the comparable period in 2021. The increase was driven by personnel expense and costs associated with ongoing clinical trials. SG&A expenses were $40.9 million for the third quarter and $20.2 million for the comparable period in 2021. The increase was primarily related to a full quarter of commercial activities for Synose, pre-launch activities for Velody, and personnel expense along with an increase in non-cash stock compensation expense. Net loss was $44.8 million or $1.07 per share for the third quarter and net loss of $34.9 million or $0.93 per share for the comparable period in 2021. The net loss for the current period included $9.2 million of non-cash stock compensation expense compared to $5.7 million in the comparable period. We ended the quarter with $227.5 million in cash and equivalents, compared to $86.5 million at December 31st, 2021. During the third quarter, we utilized our ATM facility, realizing net proceeds of $175 million. As a reminder, with the FDA approval of Avelity, up to $100 million is immediately available under our $300 million term loan facility. We believe that our current cash balance, along with the remaining committed capital from the $300 million term loan facility with Hercules Capital, is sufficient to fund anticipated operations into 2025 based on our current operating plan. I will now turn the call over to Lori for a commercial update.

Thank you, Nick, and good morning, everyone. With Sanosi and the very recent launch of Avelity, we now have two marketed products, both of which address serious conditions. I am excited to provide a commercial update for these two important and differentiated therapies. I'd first like to start with Synose. Q3 represents the first full quarter for Synose as an Axum product. As a reminder, Synose is the first and only DNRI for excessive daytime sleepiness and obstructive sleep apnea and narcolepsy, and the first and only weight-promoting agent proven to improve wakefulness through nine hours. In the quarter, total Sanosi prescription growth outpaced the wake-promoting, or WPA, market. U.S. total prescriptions for Sanosi in the third quarter grew 15% year-over-year versus the WPA market growing only 1%. Quarter-over-quarter sequential total prescription growth was 3% for Sanosi versus 0% growth for the WPA market. Our digital-centric commercialization, or DCC platform, is performing well and has contributed to increased Salesforce productivity for Synosy that is approximately twice that of prior periods and of the industry average. This contemporary, integrated, omni-channel approach to meaningful customer engagements is also being used for the launch of Avelity, and will be leveraged for the commercialization of future products in our pipeline. The growth potential for Sanosi is substantial, and we continue to estimate peak U.S. sales potential in the current indication alone of 300 to 500 million. OSA affects an estimated 22 million U.S. adults, 87% of whom experience EDS. And narcolepsy affects close to 200,000 people in the U.S., all of whom experience EDS. Sanosi currently enjoys only a 2% share of drug-treated OSA patients and a 7% share in drug-treated narcolepsy patients. We expect increased and enhanced promotional and disease education efforts to drive market share growth for Sanosi. Payer coverage for Sanosi remains broad, with 96% of commercial lives covered and 83% of total lives covered. Turning to Avelity. We announced the commercial availability of Avelity on October 20th. It is still very early days, but so far we are very encouraged by the early interest. Our field force is actively engaging healthcare providers to provide comprehensive education on availability. We are proud of the quality of our sales specialists, the vast majority of whom have prior psychiatric medication experience, including antidepressants. Guided by our DCC platform, our field force has already reached more than 15% of our prescriber target list with only 12 days on the market. With regards to payer coverage, the commercial channel is expected to be the primary channel for availability. As a rule, new therapies are generally blocked by commercial payers for the first six months after launch while they perform clinical reviews and decide on formulary placement. Interactions with commercial payers have been active and productive, and we expect some formulary decisions over the next six months. In the Medicare and Medicaid channels, antidepressants are a protected class. In order to help ensure that patients have access to and that physicians have an easy experience prescribing Ovality, we have enabled a comprehensive suite of tools and services in our patient support program, Ovality On My Side. Our patient support services include a pay no more than $10 per month savings card for eligible patients, samples, and prior authorization support for HCPs. among other tools. Major depressive disorder, or MDD, is a major public health concern with 21 million U.S. adults diagnosed in 2020, and recent publications have reported significant increase in prevalence as a result of the pandemic. We are proud to make availability available to patients living with MDD and their physicians. I will now turn the call back to Mark to lead the Q&A discussion.

Thank you, Lori. Operator, can we please have our first question? And if folks on the line that are asking questions could please be mindful of two to three questions per person, that would be fantastic, and that's just based on the size of the queue that we have. Thank you.

Thank you. If you'd like to be placed in the question queue, you can press star 1 at this time. Our first question is coming from Charles Duncan from Cancer Fitzgerald. Your line is now live.

Hi. Yeah, Ario and team, congrats on a nice quarter. Thanks for taking our questions. The first question is along the lines of commercial, and then I had a pipeline question for Lori for commercial. When you talk about a validity, what do you think, you know, I know it's only been a few days, but What do you think is most attractive to prescribers with regard to the clinical profile? Is it differentiated mechanism or onset or limited side effect or what?

Hey, Charles. Thanks for the question. It's all of the above. Like I said, our field force has been very, very active since we announced the product availability. only 12 days in the market, you know, their interactions with HGPs have been, and I just want to make sure everyone's clear, they have been full clinical reviews of availability with 15% of our target list. These are, you know, direct interactions with HGPs. So it's been really exciting to hear, you know, just how active they are and how engaged physicians are It's very hard to point to just one thing. It varies by physician, obviously, but all of the above are rising to the top.

Okay. We'll look for more color later quarters. On the pipeline, I guess on 05, Ariel, you mentioned the randomized withdrawal study has been concluded, but the double-blind study is advancing or has advanced to its started I guess I'm wondering what kind of feedback have you gotten from the agency with regard to being able to interpret randomized withdrawal? And then just a quick one on 07. What is really the gating factors to give you visibility on one year from now being able to resubmit that NDA for 07 in migraine? Thanks.

Thanks for the question, Charles. With regards to the feedback from the FDA on randomized withdrawal studies, so if you look at that design, what that design does is it provides evidence of whether or not a drug is working relative to control. That's very clear, and products have been approved, not just overall, but also in psychiatry specifically, with a randomized withdrawal study design. randomized withdrawal studies, though, they do not provide you the same information that parallel group studies provide, and that information would include a treatment effect. And with regards to your question on AXS07, I'll turn that over to Mark.

Hey, Charles. Good morning. So just the recap there, why the approximately one year or three cube next year. So FDA asked for a number of things from us with respect to CMC, including stability data on new batches that had already been made or are being made. And so just a brief background on stability data, right? That data is used to assess and inform the shelf life of an approved product, and there are various stability protocols that can be run, but typical ICH guidelines are at room temperature and accelerated conditions, and those cannot be sped up. And so, you know, typical times are zero, one month, six months, 12 months, et cetera. So it's just going through that process and generating those data.

Got it. So it's really Gantt chart. Appreciate you taking the questions. Nice quarter. Thanks. Thanks.

Thank you. Next question today is coming from Mark Goodman from SVB Security. Your line is now live.

Yes, we talked about Synosy a little bit. Just give us a sense of just what's going on behind the scenes with gross to nets, inventory changes. I know this is your first full quarter, but maybe you can talk about the product, just how the gross to nets have been throughout the year and just your payer coverage and just physician feedback on the product. Thanks.

Yeah, great. Thanks for the question. I think Nick will take the gross-to-net question, and Lori will comment on what's going on behind the scenes, inventory changes, et cetera.

Hey, Mark. Good morning. So first, your question on gross-to-net. As we said on the investor call, we expected gross-to-net to be at around 50%, which is kind of what we're seeing. It's been pretty consistent. And then as it relates to inventory, The sales for the quarter really are not impacted by any type of inventory build or channel, inventory in the channel. Essentially, I guess Q2 of the $8.8 million, obviously we had to load the channel to start with. And then for Q3, though, I think it's a pretty steady state. So really no inventory impact from during the quarter. Corey?

Yeah, hi, Mark, and I'll just add on payer coverage. You know, our payer coverage has maintained exactly what it was when we acquired the product back in May. There's been no payer coverage changes.

Thank you. Our next question is coming from June Lee from Truist Securities. Your line is now live.

Hi, thanks for taking our questions. In addition to VIVA systems, are you supplementing your efforts with services from IQVIA? Our understanding is that due to the ongoing litigation between VIVA and IQVIA, VIVA clients are blocked from certain services provided by IQVIA. Just wanted to understand the flexibility of your DCC efforts. And on the pipeline, what can we expect in terms of the kinds of data you will share for CORD by year end? And are there any material differences between the designs of Advance 1 and 2? Thank you.

Hey, June. Thanks for the question. So, yeah, so let me just recap from DCC how our infrastructure is built, and then I can answer your question around IQVIA. So, you know, as we've stated in the past, our DCC platform is really built off of Viva as foundational, and it is supplemented by several different additional tools and analytical machine learning, AI offerings. IQVIA, the limitation with Viva and IQVIA, we're not impacted by that at all. We actually use Symfony data, and so they're very interchangeable, and that is what feeds through the Viva system. So there's really no impact to us in terms of what our offerings look like.

And then, June, with regards to your other two questions, the Accord data that's expected by year-end will be top-line results from the Accord trial. So we look forward to unblinding that study and reporting to you the results as it will provide additional information with regards to the activity of the product in this patient population. As a reminder, the Advance One trial was a very positive study. And while the ACCORD trial, while the powering of that study is going to be reduced because we stopped it in order to initiate the Advance 2 trial, we do think that there is the possibility that the results will provide us information directionally, which could support the activity of the product With regards to the question on advance one and advance two, there are no material differences in terms of the design of those studies. So they're pretty much identical study designs.

Thank you. Thank you. Next question is coming from Jason Burberry from Bank of America. Your line is now live.

Hey, good morning. Thanks for taking my questions. I'm wondering if you can just talk a little bit about Avelides insurance mix and how that impacts gross to net in, say, the first six to nine months. I know you guys have been out talking about sort of the challenge with commercial coverage in the early days. So just kind of wondering how you anticipate sort of revenue capture on a per-script basis. And maybe, Laurie, if you can comment on sort of effectively, you know, the Amgen kind of free-script model with CGRP antibodies out of the gate, if that's something that you can kind of leverage to get early awareness and utilization of availability. in the marketplace? And then also just on the DCC program with Synosy, what's the right amount of time to assess the effectiveness of DCC as it pertains to Synosy? Thanks.

Hey, Jason, thanks for the questions. A lot packed in there. So let me just start from the beginning. So the commercial channel is expected to be our primary channel for ability. And as a rule, new therapies, across the board, regardless of therapeutic class, are generally blocked by commercial payers for a period of time after approval while those payers perform their clinical reviews and decide on formulary placement. This does not mean that patients, that they will not cover patients during this time if HTPs fill out the appropriate paperwork. That is one of the reasons why we have a robust prior authorization support system in place as well as our ability on my side copay card program for patients to make sure that they have affordable access to that therapy. We have been very active in our communications with commercial payers. Those have been very productive since the announcement of launch, or the approval, and even more so after launch. And we do expect some of those formula decisions to be made over the next six months. And as a reminder, there will be some volume that comes through the Medicare and Medicaid channel, that is a protected class in those channels. I'll switch over to your question around the Amgen playbook of providing free scripts. That is not what we're set up to do and or doing. We are providing a copay card and assistance to patients so that patients are effectively getting a drug at a very affordable rate while their physicians are filling out the appropriate paperwork to inform payers that we need and would like to have meaningful coverage. I believe you then asked a question on DCC and the program with Sanosi and how we can see impacts there. As I mentioned in my prepared remarks, we are already seeing the effects of DCC with the Sanosi field force. We have a field force roughly half the size of prior quarters, and we're maintaining the exact same productivity as those prior quarters. We're really encouraged by this as we continue our relaunch efforts of Sanosi. We are in the process of ensuring that our targets are the appropriate targets who have enough appropriate patients to really drive meaningful growth. And our sales reps are, you know, really highly experienced sales reps with an incredible leadership team. And we see that coupled with, you know, additional focus on disease education and additional promotional spend as our avenue for growth.

Got it. Great. Thanks. Thank you. Next question is coming from Joseph Tome from Cowan & Company. Your line is now live.

Hi there, good morning, and thank you for taking our questions. Maybe a first one just on, I know it's only been a couple weeks here, but where is the initial demand coming from? Kind of where are these patients at within their treatment journey? And do you expect that to change over time? And now that it already is approved in the U.S., maybe what are your updated thoughts on ex-U.S. approvals or licensing? Thank you.

Yeah, hey Joseph, thanks for the question. So as you would expect, I mean, you know, again, it's only... it's only 12 days on market. But what we're seeing in these very early days is exactly what you would expect. So the scripts are coming primarily from psychiatrists with, you know, a nice handful from PCPs. Where patients are in terms of their treatment journey, it's all over the place. And that is likely supported by the fact, you know, that the clinical profile of Abelity has data in a very robust way in broad subsets of patient groups. So physicians are really finding patients across the board. You know, if they are a candidate for Avelity, right now it's a little bit too early to tell which lines of therapy we're concentrating on. And I'll turn it over to Nick for the XUS.

Hi, Joe. Yeah, so I'm in for Avelity right now. As we've always stated, we're always looking for XUS partners. That's how we've consistently stated. And then for CINOSI, we'll be, from an XUS standpoint, as we stated in our opening comments, we are expecting to close on the XUS portion of CINOSI this quarter.

Great. And then maybe if I could just do one on the pipeline. In terms of AXS-12, is all you need for a regulatory submission this upcoming Phase 3 data? Is there any additional CMC work that would need to be completed for this therapy ahead of an NDA submission. Great, thanks.

Hey, it's Mark and Joe. For AXS-12, there is work that's ongoing for CMC. And just a reminder, the API is a custom synthesis process that we oversee, as well as drug products. So all the work to support registration batches, et cetera, is under way.

Thank you.

Thank you. Next question is coming from Yatin Suneja from Google Home Partners. Your line is now live.

Hey, guys. Thank you for taking my question. Just a couple for me. First one is on the sampling. Can you just comment on whether you are doing sampling? How are the sampling set up? You know, is it like a weekly pack, two-week pack? And then maybe also comment on if somebody starts on a sample, how that reimbursement works. So that's first part. Second is around how are you recognizing revenues? If you can just tell us what does that entail? And then finally, you know, the RX data or the TRX data that's available to third party, how accurate that is? Should we use that to help model the launch? Thanks.

Great. Thanks for the question. So Laurie will handle the sampling. question and also the data reporting, and Nick will handle the revenue recognition.

Hey, Yatin. Good morning. So, in regards to samples, so the way that we are distributing samples right now is that HCPs can order the samples online or when their rep comes into the office. So, they are electronic samples. They are shipped to them Typically when, you know, it obviously varies by HCP, but most likely what will happen is that physicians will hand samples to a patient and then hand the script or file the EMR script at the same time through the EMR system. In terms of size, it is a two-week model.

Great. And then as it relates to the revenue, so we are in a title model. So as such, once inventory transfers from our warehouse to the distributor, sale is recorded, risk of loss is passed at that point, title is transferred, and then we are booking associated gross to net accruals against those gross sales.

And I'll answer the data reporting side. So both Symphony and IQVIA, especially in early days, it is very hard for them to predict what the capture rate is in terms of capturing all national scripts. So there is always a factor applied. We have found that they are both very close to expectations. We see no reason why their capture rates, they'll be tweaked and get better over the course of the next couple of coming weeks. as data gets reconciled. But it's turning in the right direction.

Got it. Just one quick, if I may. What about the inventory? How are you managing that? Is there a target? Like, you know, you need to be in the two-week range. Just if you can comment, and I'll get back in the queue. Thank you.

Yeah, that's correct. So with the title model, it's pretty easy to ensure that supply is in the channel. So there's roughly basically two weeks at any given time that's in the channel. And that's currently how we're seeing it.

Thank you. Next question today is coming from Rick from Morgan Stanley. Your line is now live.

Hi, good morning. Thanks for taking our questions. We had two both related to what you learned about duration of use for Abelity in the early phase of the launch. So question one, how many bottles of treatment do you think one prescription currently represents, and how do you think this could evolve once the launch is in more of a steady state? And then secondly, more broadly, what are your current thoughts on how many bottles of Abelity per year you think the average patient would use, again, once the launch is in kind of a full-blown steady state? Thanks.

Thanks for the question. We've been on the market 12 days, so it's a little bit early to be able to provide you with any credible answer to the duration of use and also to the duration of use. With regards to what the scripts represent, I think it's pretty clear, but Laurie, could you maybe clarify?

Yeah, that's exactly what I would say. It's a little bit too early, but we do The PI is very clear on dosing, so we fully intend and expect for a 30-day script should be two bottles. And again, it's too early for us to have any data behind that.

But that's what we're seeing. That's exactly what we're seeing.

Thank you. Our next question is coming from Chris Howardson from Jefferies. Your line is now live.

Great. Thank you so much. I just had two quick questions. One was with respect to the Sanosi commercial launch. Could you give us a sense of the split between OSA and narcolepsy? And I guess the follow-up to that, you know, what would be the strategy to maximize revenues in narcolepsy, assuming success, excuse me, in 012? And then the second question I had is just a curiosity with respect to the new mechanism that was discovered for CINOSI. Any plans to capitalize on the TAR-1 agonism in any way or just an interesting finding that you found about the molecule? Thank you.

Great. So, Laura, maybe comment on the split between OSA and narcolepsy in terms of scripts, and then I'll take the other questions.

Sure. Hey, Chris. Yeah, so right now the current script split is about 70 OSA, 30% narcolepsy. And, you know, the OSA market is a massive market, right? 22 million patients suffer from OSA versus 200,000 in narcolepsy. There's definitely room to grow in both. And, you know, it's a bit premature to talk about how we'll work with 12, but, you know, Synose is indicated for EDS in narcolepsy only, and so we will make sure that early treatment for narcolepsy is capitalized on, since that is usually one of the first symptoms that is present in diagnosis.

Great. With regards to your question around synose in narcolepsy versus AXS-12, Just one thing to remember is that AXS-12 is being developed for cataplexy in narcolepsy. So synosy is the indication is excessive daytime sleepiness in patients with narcolepsy, and no activity has been seen with regards to cataplexy. So the products are complementary. And as it relates to the new mechanism of action for synosy, which is a tolerant agonism, So how could that be important? I think the first thing is the realization that there is this differentiating mechanism for sorianfetol. And secondly, the TAR1 mechanism has been shown to be pro-cognitive. So therefore, it does relate to the potential effect of the drug on cognition. And we did announce the results of the SHARP study in patients who were cognitively impaired, you know, with OSA and EDS, and what it showed was a statistically significant and robust effect on cognition with Synozy as compared to placebo. You know, we do also like this mechanism of action as it relates potentially to the indication of ADHD, and as we mentioned, we are on track to initiate a Phase III trial, a Phase II-III trial, in ADHD with Synovial Solianfetol in the fourth quarter, which is this quarter.

Okay. Thank you so much. Appreciate it.

Thank you. Next question is coming from David Holm from SMBC .

Hey. Thanks so much for taking the questions and congrats on the quarter. Just had a couple. So with the ADA indication for AXS05, can you just remind us again, walk us through the different scenarios that are possible there. So the Accord randomized withdrawal study is positive. Do you still intend to file for approval based on that data? And then, you know, if it's not, then is the plan that you would need the ADVANCE-2 data to support the filing? Is there any, are there any other, you know, alternatives besides those pathways?

So, the way that we are approaching it is that we intend to have Advance 2 read out before we file an NDA. We want to ensure that we have a robust package. As you are implying, there are a lot of different factors, and we'll know a lot more once we read out the accord trial. But right now, our working assumption is that ADVANCE-2 would serve as the second positive trial for an NDA.

I see. That's helpful. And then just in terms of the OVALITY launch, I guess, you know, a lot of the, I think a lot of the prior questions had addressed most of it, but in terms of as we get deeper into the launch and have several full quarters under our belt, Are there metrics that you plan to report regularly on earnings goals, be it scripts, numbers of patients treated, and would you provide guidance in terms of revenues for any of the products?

Yeah, so I'll answer the first one, and then I'll kick it over to Nick. But what we will definitely report on, obviously, will be scripts as well as HGP adoption and riders. as we get deeper into the quarters.

Yeah, and just to add to that, we would also be reporting on payer coverage because we think that that's obviously relevant and of interest. Absolutely.

And as for revenue guidance, obviously we're in extremely early days, the embryonic days of the launch right now. So as we progress and grow and as we see access evolve, we'll be able to have better sense of where we expect to land. So down the road, potentially yes, but obviously way too early to give any sort of guidance or expectations of when guidance would be given.

Thank you. Next question today is coming from Greg Sunabaja from Mizuho Securities. Your line is now live.

Great. Good morning. Thanks for taking my question, and congrats on the quarter. I know you've had a lot of success with DCC, but my question has to do with kind of are there plans in the works right now for thinking about a direct-to-consumer campaign, just any other color on additional marketing and advertising plans for Abelity? Thanks.

Yeah, hi, thanks for the question. So coming out of the gate for the launch, we want to make sure that HTPs are very much aware of the product and prepared to prescribe if a patient were to walk into the office and ask for the product. We are doing that through very strategic and targeted media spends to HTPs, but also to patients. And so we believe in the early days that it's important to make sure that we have a very thoughtful approach to how we deploy media to consumers, and that is something that we will continue to expand upon and ramp up as we get deeper and deeper into launch.

Thank you. Next question today is coming from Matt Kaplan from Lattenburg-Fallman. Your line is now live.

Hi. Good morning. Just a quick follow-up on your Sanosi ADHD program that you plan to launch later this year. Given the, I guess, impact on cognition that you saw in the SHARP study, are you going to incorporate any of those aspects in the phase two, three study for ADHD for Sanosi?

Thanks for the question, Matt. We'll be providing details on the exact design of the study once we launch it. Obviously, we are considering the results from the SHARP study as it might relate to exploration of the product in ADHD. There may be something that we could look at or that we might want to look at. We'd have to determine how best to do that and whether it makes sense to do that. The measures are different, but obviously cognition or an increase in concentration is an important part of ADHD.

Great. Thanks for taking the question.

Thank you. Next question is coming from Miles Minter from William Blair. Your line is now live.

Hey, everyone. Thanks for taking the questions. Just the first one, are you aware of any major payers since the Evality launch that have progressed through their P&T meetings or at least have them scheduled? And I guess what proportion of covered lives those payers would represent? Thanks.

Hey, Myles. Thanks for the question. Yeah, so as we mentioned earlier, those discussions are active and progressing, but we've general rule. They're usually blocked for some period of time right after launch so that they can complete their process. Right now, only the Medicare, Medicaid channel, given that it's a protected class, is covered. But as we mentioned previously, the commercial channel will be the primary channel for availability.

Okay, cool. And then quick follow-up just on the free sampling program. If you give those to patients, do those end patients have to have a clear path to reimbursement after their two-week script is finished? Thanks.

No. So the samples are up to the physician to provide to the patient. So the physician is well within his right to provide samples to his patient and decide when and how to write a script.

Beautiful. Thank you.

Thank you. Our final question today is coming from Bert Haslett from BTIG. Your line is now live.

Thank you for taking the question. Mine's very straightforward. Is there upside to the advance to trial timing? Is 2025 conservative? Thank you and congratulations on all the progress.

So that timing reflects what is on clinicaltrials.gov. And I think it's too early to decide how much leeway there could be in that timing. We think that it is overall conservative, but it is a placeholder. And as the study gets underway further, and as we have more information in terms of initial enrollment, then that will allow us to provide more granularity on the timing of study readout.

Thank you. We've reached the end of our question and answer session. I'd like to turn the floor back over for any further or closing comments.

Well, you know, thank you again for joining us on the call today. At Axone, we are committed to bringing essentially life-changing medicines to people living with serious CNS conditions. With the commercialization of Synose, the launch of Avelity, and our broad late-stage pipeline, the hard work of the Axon team is translating into tangible and meaningful benefits to patients and their healthcare providers. We look forward to updating you over the coming months on our continued commercial and development pipeline progress. Have a great day.

Thank you. That does conclude today's teleconference and webcast. You may disconnect your line at this time, and have a wonderful day. We thank you for your participation today.